Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Kevin Zarca; Maroua Mimouni; Helena Pereira; Gilles Chatellier; Valérie Vilgrain; Isabelle Durand-Zaleski; Eric Assenat; Elisabeth Delhom-Christol; Boris Guiu; Alina Ilonca; Julie Lonjon; Georges-Philippe Pageaux; Mohamed Abdel-Rehim; Wassim Al-Laham; Mohamed Bouattour; Laurent Castera; Arnaud Dieudonné; Rachida Lebtahi; Maxime Ronot; Annie Sibert; Hélène Barraud; Christophe Bazin; Jean-Pierre Bronowicki; Valérie Laurent; Elodie Mathias; Carine Chagneau-Derrode; Rémy Perdrisot; Christine Silvain; Jean-Pierre Tasu; Patrick Borentain Renégerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Antoine Bouvier; Olivier Couturier; Frédéric Oberti; Laurent Vervueren; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sar-Ran; Julia Chalaye; Charlotte Costentin; Emmanuel Itti; Hicham Kobeiter; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Julien Edeline; Etienne Garin; Yan Rolland; Isabelle Archambeaud; Thomas Eugene; Eric Frampas; Christophe Cassinotto; Martine Guyot; Jean-Baptiste Hiriart; Bruno Lapuyade; Julien Vergniol; Philippe Bachellier; Julien Detour; Bernard Duclos; Michel Greget; Francois Habersetzer; Alessio Imperiale; Philippe Merle; Agnès Rode; Julie Morvan; Eric Nguyen-Khac; Thierry Yzet; Guillaume Baudin; Patrick Chevallier; Abakar Mahamat; Thierry Piche; Micheline Razzouk; Patrick Hillon; Romaric Loffroy; Michel Toubeau; Julie Vincent; Gabriele Barabino; Nadia Bouarioua; Muriel Cuilleron; Marie Ecochard; Nathalie Prevot-Bitot; Vincent Leroy; Julie Roux; Christian Sengel; Valérie Bourcier; Nathalie Ganne- Carrie; Olivier Seror; Sylvie Costo; Thông Dao; Jean-Pierre Pelage; Jérôme Dumortier; Francesco Giammarile; Pierre-Jean Valette; Nadia Ghazzar; Olivier Pellerin; Julien Taieb; Pierre Weinmann; Alexandra Heurgue- Berlot; Claude Marcus; Daniele Sommacale; Maria-Angéla Castilla-Lièvre; Sophie Maitre; Lysiane Marthey

doi:10.1016/j.clinthera.2021.04.018

Back

Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Journal article

Open access

Peer reviewed

Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Kevin Zarca, Maroua Mimouni, Helena Pereira, Gilles Chatellier, Valérie Vilgrain, Isabelle Durand-Zaleski, Eric Assenat, Elisabeth Delhom-Christol, Boris Guiu, Alina Ilonca, …

Clinical Therapeutics, Vol.43(7), pp.1201-1212

28/05/2021

DOI: https://doi.org/10.1016/j.clinthera.2021.04.018

Abstract

Cost-utility analysis

Hepatocellular carcinoma

Sorafenib

Survival analysis

Yttrium radioisotopes

Purpose: The SARAH (Sorafenib Versus Radioembolization in Advanced Hepatocellular Carcinoma) trial (ClinicalTrials.gov Identifier NCT01482442) did not show a significant survival benefit for patients treated with transarterial radioembolization (TARE) compared with continuous oral sorafenib. The improved toxicity profile of patients treated with TARE in the trial, however, could result in a quality of life benefit in economic evaluations. Our objective was to perform a cost-utility analysis of TARE versus sorafenib for locally advanced and inoperable hepatocellular carcinoma.Methods: This study used patient-level data of the SARAH trial regarding resource use, progression-free and overall survival, and quality of life for the within-trial period for the patients who received at least 1 dose of sorafenib or 1 treatment with TARE according to their randomization arm. Data were extrapolated by using a partitioned survival model that incorporated costs and health outcomes, measured in life-years and quality-adjusted life-years (QALYs).Findings: The use of TARE resulted in an average loss of 0.036 life-year and a gain of 0.006 QALY compared with sorafenib. The aerage cost for the TARE arm was €17,179 (95% CI, 9,926-24,280) higher than the sorafenib arm, for an incremental cost-effectiveness ratio of €3,153,086/QALY. The probabilistic sensitivity analysis revealed a 50% risk that the TARE strategy was dominated. TARE was consistently dominated by sorafenib or had an incremental cost-effectiveness ratio more than €450,000/QALY in all sensitivity analyses.Implications: This economic evaluation of SARAH found that using radioembolization with yttrium-90 microspheres for the treatment of hepatocellular carcinoma was not a cost-effective option at the usually accepted willingness-to-pay thresholds.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1016/j.clinthera.2021.04.018View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma
Creators - without role: Kevin Zarca - Centre de Recherche Épidémiologie et Statistique
Maroua Mimouni - Assistance Publique – Hôpitaux de Paris
Helena Pereira - Hôpital Européen Georges-Pompidou
Gilles Chatellier - Hôpital Européen Georges-Pompidou
Valérie Vilgrain - Centre de Recherche sur l'Inflammation
Isabelle Durand-Zaleski - Assistance Publique – Hôpitaux de Paris
Eric Assenat - Hôpital Saint Eloi
Elisabeth Delhom-Christol - Hotel Dieu Hospital
Boris Guiu - Hôpital Saint Eloi
Alina Ilonca - Hotel Dieu Hospital
Julie Lonjon - Hotel Dieu Hospital
Georges-Philippe Pageaux - Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi]
Mohamed Abdel-Rehim - Hotel Dieu Hospital
Wassim Al-Laham
Mohamed Bouattour - Hotel Dieu Hospital
Laurent Castera - Hotel Dieu Hospital
Arnaud Dieudonné - Hotel Dieu Hospital
Rachida Lebtahi - Hotel Dieu Hospital
Maxime Ronot - Hotel Dieu Hospital
Annie Sibert - Hotel Dieu Hospital
Hélène Barraud - Hotel Dieu Hospital
Christophe Bazin - Hotel Dieu Hospital
Jean-Pierre Bronowicki
Valérie Laurent - Université Paris Cité
Elodie Mathias - Hotel Dieu Hospital
Carine Chagneau-Derrode - Hotel Dieu Hospital
Rémy Perdrisot - Hotel Dieu Hospital
Christine Silvain - Hotel Dieu Hospital
Jean-Pierre Tasu - Cereep Ecotron Île-de-France
Patrick Borentain Renégerolami - Hotel Dieu Hospital
Olivier Mundler - Hotel Dieu Hospital
Jean-Francois Seitz
Vincent Vidal - Hotel Dieu Hospital
Christophe Aubé - Hotel Dieu Hospital
Antoine Bouvier - Assistance Publique – Hôpitaux de Paris
Olivier Couturier - Hotel Dieu Hospital
Frédéric Oberti - Hotel Dieu Hospital
Laurent Vervueren - Hotel Dieu Hospital
Isabelle Brenot-Rossi - Assistance Publique – Hôpitaux de Paris
Jean-Luc Raoul
Anthony Sar-Ran
Julia Chalaye - Assistance Publique – Hôpitaux de Paris
Charlotte Costentin - Hotel Dieu Hospital
Emmanuel Itti - Hotel Dieu Hospital
Hicham Kobeiter - Assistance Publique – Hôpitaux de Paris
Alain Luciani - Assistance Publique – Hôpitaux de Paris
René Adam - Hotel Dieu Hospital
Maïté Lewin - Hotel Dieu Hospital
Didier Samuel - Hotel Dieu Hospital
Julien Edeline - Hotel Dieu Hospital
Etienne Garin - Hotel Dieu Hospital
Yan Rolland - Hotel Dieu Hospital
Isabelle Archambeaud - Inserm
Thomas Eugene - Hotel Dieu Hospital
Eric Frampas - Hotel Dieu Hospital
Christophe Cassinotto - Hotel Dieu Hospital
Martine Guyot - Hotel Dieu Hospital
Jean-Baptiste Hiriart
Bruno Lapuyade - Hotel Dieu Hospital
Julien Vergniol - Hotel Dieu Hospital
Philippe Bachellier - Assistance Publique – Hôpitaux de Paris
Julien Detour - Hotel Dieu Hospital
Bernard Duclos - Assistance Publique – Hôpitaux de Paris
Michel Greget - Assistance Publique – Hôpitaux de Paris
Francois Habersetzer - Assistance Publique – Hôpitaux de Paris
Alessio Imperiale - Assistance Publique – Hôpitaux de Paris
Philippe Merle - Hotel Dieu Hospital
Agnès Rode - Cereep Ecotron Île-de-France
Julie Morvan - Hotel Dieu Hospital
Eric Nguyen-Khac - Hotel Dieu Hospital
Thierry Yzet - Hotel Dieu Hospital
Guillaume Baudin - Hotel Dieu Hospital
Patrick Chevallier - Hotel Dieu Hospital
Abakar Mahamat - Hotel Dieu Hospital
Thierry Piche - Hotel Dieu Hospital
Micheline Razzouk - Hotel Dieu Hospital
Patrick Hillon - Assistance Publique – Hôpitaux de Paris
Romaric Loffroy - Equipe IFTIM [ImViA - EA7535]
Michel Toubeau - Hotel Dieu Hospital
Julie Vincent - Hotel Dieu Hospital
Gabriele Barabino - Hotel Dieu Hospital
Nadia Bouarioua - Hotel Dieu Hospital
Muriel Cuilleron - Hotel Dieu Hospital
Marie Ecochard - Assistance Publique – Hôpitaux de Paris
Nathalie Prevot-Bitot
Vincent Leroy - Hotel Dieu Hospital
Julie Roux - Hotel Dieu Hospital
Christian Sengel - Hotel Dieu Hospital
Valérie Bourcier - Assistance Publique – Hôpitaux de Paris
Nathalie Ganne- Carrie
Olivier Seror - Hotel Dieu Hospital
Sylvie Costo - Hotel Dieu Hospital
Thông Dao - Cereep Ecotron Île-de-France
Jean-Pierre Pelage
Jérôme Dumortier - Hotel Dieu Hospital
Francesco Giammarile - Cereep Ecotron Île-de-France
Pierre-Jean Valette - Hotel Dieu Hospital
Nadia Ghazzar - Hotel Dieu Hospital
Olivier Pellerin - Hotel Dieu Hospital
Julien Taieb
Pierre Weinmann - Hotel Dieu Hospital
Alexandra Heurgue- Berlot
Claude Marcus - Hotel Dieu Hospital
Daniele Sommacale - Hotel Dieu Hospital
Maria-Angéla Castilla-Lièvre - Hotel Dieu Hospital
Sophie Maitre - Hotel Dieu Hospital
Lysiane Marthey - Hotel Dieu Hospital
Publication Details: Clinical Therapeutics, Vol.43(7), pp.1201-1212
Identifiers: 9936349809311
Academic Unit: Institut de Génétique Moléculaire de Montpellier - IGMM
Language: English
Resource Type: Journal article
Local Fields: hal-03617593